Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients

Dong, Ying; Wang, Pan; Jiao, Jie; Yang, Xinchun; Chen, Mulei; Li, Jing

doi:10.3389/fcell.2022.861829

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a recent study examining the intestinal microflora in men and women treated with an ACE inhibitor or an ARB showed a progressive improvement in gut microbial composition that correlated with the level of BP control in both sexes. 81…”

Section: Intestinal Actions Of Medicationsmentioning

confidence: 99%

Antihypertensives and Antibiotics: Impact on Intestinal Dysfunction and Hypertension

et al. 2023

View full text Add to dashboard Cite

Gut dysfunction has emerged as a contributor to hypertension, the leading risk factor for disease globally, including stroke, heart failure, and kidney disease. This is underpinned by breakdown of the homeostatic relationship connecting intestinal epithelial function, the microbiota and immune responses. Antihypertensive medications have been shown to reverse intestinal dysfunction and gut dysbiosis. However, the mechanisms underlying this restoration of gut structure and function remain largely unknown. In this review, we examine current knowledge supporting a role for impaired intestinal epithelial permeability in hypertension, focusing on electrolyte movement, the renin-angiotensin-aldosterone system, and the restorative effects of orally administered antihypertensive medications and antibiotics. Further work is required to determine if the association between intestinal dysfunction and hypertension is causal. This is a rapidly evolving field, with intestinal dysfunction and dysbiosis representing an area that may be exploited to improve treatment of hypertension and cardiovascular disease.

show abstract

Section: Intestinal Actions Of Medicationsmentioning

confidence: 99%

Antihypertensives and Antibiotics: Impact on Intestinal Dysfunction and Hypertension

et al. 2023

View full text Add to dashboard Cite

show abstract

Intestinal microbiota by angiotensin receptor blocker therapy exerts protective effects against hypertensive damages

Li,

Wang,

Yan

et al. 2024

iMeta

View full text Add to dashboard Cite

Dysbiosis of the gut microbiota has been implicated in hypertension, and drug–host–microbiome interactions have drawn considerable attention. However, the influence of angiotensin receptor blocker (ARB)‐shaped gut microbiota on the host is not fully understood. In this work, we assessed the alterations of blood pressure (BP), vasculatures, and intestines following ARB‐modified gut microbiome treatment and evaluated the changes in the intestinal transcriptome and serum metabolome in hypertensive rats. Hypertensive patients with well‐controlled BP under ARB therapy were recruited as human donors, spontaneously hypertensive rats (SHRs) receiving normal saline or valsartan were considered animal donors, and SHRs were regarded as recipients. Histological and immunofluorescence staining was used to assess the aorta and small intestine, and 16S rRNA amplicon sequencing was performed to examine gut bacteria. Transcriptome and metabonomic analyses were conducted to determine the intestinal transcriptome and serum metabolome, respectively. Notably, ARB‐modified fecal microbiota transplantation (FMT), results in marked decreases in systolic BP levels, collagen deposition and reactive oxygen species accumulation in the vasculature, and alleviated intestinal structure impairments in SHRs. These changes were linked with the reconstruction of the gut microbiota in SHR recipients post‐FMT, especially with a decreased abundance of Lactobacillus, Aggregatibacter, and Desulfovibrio. Moreover, ARB‐treated microbes contributed to increased intestinal Ciart, Per1, Per2, Per3, and Cipc gene levels and decreased Nfil3 and Arntl expression were detected in response to ARB‐treated microbes. More importantly, circulating metabolites were dramatically reduced in ARB‐FMT rats, including 6beta‐Hydroxytestosterone and Thromboxane B2. In conclusion, ARB‐modified gut microbiota exerts protective roles in vascular remodeling and injury, metabolic abnormality and intestinal dysfunctions, suggesting a pivotal role in mitigating hypertension and providing insights into the cross‐talk between antihypertensive medicines and the gut microbiome.

show abstract

Gut Dysbiosis and Cardiovascular Health: A Comprehensive Review of Mechanisms and Therapeutic Potential

Trehan,

Singh,

Bector

et al. 2024

Cureus

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a leading cause of mortality worldwide. Recent research has identified gut dysbiosis - an imbalance in the gut microbiota - as a significant factor in the development of CVDs. This complex relationship between gut microbiota and cardiovascular health involves various mechanisms, including the production of metabolites such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs). These metabolites influence lipid metabolism, inflammation, and blood pressure regulation. In addition, the gut-brain axis and neurohormonal pathways play crucial roles in cardiovascular function. Epidemiological studies have linked gut dysbiosis to various cardiovascular conditions, highlighting the potential for therapeutic interventions. Dietary changes, probiotics, and prebiotics have shown promise in modulating gut microbiota and reducing cardiovascular risk factors. This underscores the critical role of gut health in preventing and treating CVDs. However, further research is needed to develop targeted therapies that can enhance cardiovascular outcomes.

show abstract

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients

Cited by 3 publications

References 49 publications

Antihypertensives and Antibiotics: Impact on Intestinal Dysfunction and Hypertension

Antihypertensives and Antibiotics: Impact on Intestinal Dysfunction and Hypertension

Intestinal microbiota by angiotensin receptor blocker therapy exerts protective effects against hypertensive damages

Gut Dysbiosis and Cardiovascular Health: A Comprehensive Review of Mechanisms and Therapeutic Potential

Contact Info

Product

Resources

About